Sage Therapeutics Stock Soars

Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial instability. Learn more on SAGE stock here.
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Biogen proposes acquisition of partner Sage Therapeutics
The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.
1SAGE, BIIB : Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy:...
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Biogen Wants to Buy Its Partner Sage for Almost No Premium
Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01. Sage’s board will now review and evaluate the offer,
Sage Shares Surge Premarket After Biogen Proposes Takeover
Shares of Sage Therapeutics jumped nearly 40% in premarket trading Monday after the biopharmaceutical company received an unsolicited buyout bid from partner Biogen. Biogen, which already owns a roughly 10.
BioPharma Dive3d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
pharmaphorum4d
Biogen offers to buy out wilting Sage for $442 million
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...
BioSpace4d
Biogen Submits Offer to Buy Embattled Partner Sage
Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...
Biogen CEO sees no burning need for more acquisitions
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...
FiercePharma4d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
STAT3d
Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’
Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
Morgan Stanley analyst Vikram Purohit has maintained their neutral stance on SAGE stock, giving a Hold rating on January 7.Stay Ahead of the ...